VK2735
vs Enicepatide.
Compare VK2735 and enicepatide by GLP-1/GIP mechanism, oral and injectable routes, Phase 2 evidence, Phase 3 programs, tolerability, and approval status.
What is the difference?
VK2735 and enicepatide are different investigational GLP-1/GIP dual agonists with no head-to-head trial. VK2735 is a Viking Therapeutics program being studied as both a weekly injection and daily tablet. Enicepatide, formerly CT-388, is Roche's signal-biased once-weekly injectable program. VK2735 has two 13-week Phase 2 formulation records and fully enrolled injectable Phase 3 trials. Enicepatide has a 48-week Phase 2 result and recruiting Phase 3 trials. Neither is FDA approved, and matching receptor labels do not make their doses, percentages, tolerability, or future products interchangeable.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
VK2735
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection and once-daily oral tablet
- Registry
- 5 matched NCT records
- Sponsor
- Viking Therapeutics
Enicepatide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 8 matched NCT records
- Sponsor
- Roche / Carmot Therapeutics
VK2735 vs Enicepatide: how direct is the evidence?
No participant in the cited sources was randomized between VK2735 and Enicepatide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
VK2735
GIP and GLP-1 receptor dual agonist
- Route
- Once-weekly subcutaneous injection and once-daily oral tablet
- Stage
- Subcutaneous Phase 3 active; oral Phase 3 planned
- Status
- Investigational - not FDA approved
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialEnicepatide
Signal-biased GLP-1 + GIP receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 ENITH program recruiting
- Status
- Investigational - not FDA approved
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 0
- Results posted
- 0
- Recruiting site observations
- 0
matched NCT records
- Recruiting
- 4
- Results posted
- 0
- Recruiting site observations
- 339
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
VK2735
GIP and GLP-1 receptor dual agonist
- Route
- Once-weekly subcutaneous injection and once-daily oral tablet
- Stage
- Subcutaneous Phase 3 active; oral Phase 3 planned
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT06068946 · NCT06828055 · NCT07104500 · NCT07104383
Enicepatide
Signal-biased GLP-1 + GIP receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 ENITH program recruiting
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT06525935 · NCT07351045 · NCT07351058 · NCT04838405
Compare the field, then read the limit.
This is the closest mechanism-level comparison in the current pipeline set because both activate GLP-1 and GIP receptors. That similarity makes it tempting to rank their largest reported percentages or treat one as an oral version of the other. A useful comparison must instead separate molecular design, formulation, trial duration, result definition, placebo adjustment, adverse-event discontinuation, Phase 3 timing, and the absence of randomized comparative evidence.
| Field | VK2735 | Enicepatide | How to interpret it |
|---|---|---|---|
| Core mechanism | GLP-1 and GIP receptor dual agonist | Signal-biased GLP-1 and GIP receptor dual agonist | The headline receptors overlap, while molecular signaling and pharmacology differ and do not establish a clinical winner on their own. |
| Formulations studied | Weekly subcutaneous injection and daily oral tablet | Weekly subcutaneous injection | An oral formulation expands VK2735's research program, but it does not make VK2735 a substitute for enicepatide or an approved pill. |
| Phase 2 evidence | Up to 14.7% injectable and 12.2% oral mean change at 13 weeks | 22.5% placebo-adjusted efficacy estimate and 18.3% treatment-regimen estimate at 48 weeks | Duration, placebo adjustment, estimand, formulation, and dose strategy prevent a direct percentage ranking. |
| Phase 3 program | VANQUISH-1 and VANQUISH-2 fully enrolled | ENITH-1 and ENITH-2 recruiting | The programs are at different operational milestones, but neither has an FDA-approved indication or published Phase 3 outcome. |
| Identity boundary | Viking VK2735 clinical program | Roche enicepatide, formerly CT-388, clinical program | A shared receptor class cannot authenticate an online product or transfer sponsor evidence, formulation, or regulatory status between names. |
Why the headline numbers do not name a winner.
VK2735's injectable Phase 2 study reported up to 14.7% mean change at 13 weeks, and its separate oral study reported up to 12.2%. Roche reported 22.5% placebo-adjusted weight loss for enicepatide at 48 weeks under an efficacy estimand and 18.3% under a treatment-regimen estimand. These figures answer different statistical questions over different durations. No valid subtraction, weekly-rate calculation, noninferiority conclusion, or winner claim can be drawn without a common randomized protocol.
Keep the comparison honest.
- 01
Compare the 13-week and 48-week records as separate studies, not as linear rates or proof that one program reaches a stronger endpoint faster.
- 02
Keep raw mean change, placebo-adjusted change, treatment-regimen estimates, and efficacy estimates labelled exactly as the source reports them.
- 03
Do not treat receptor overlap, Phase 3 activity, or an online listing as evidence of equivalence, approval, commercial availability, or sponsor-authenticated material.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →